Trends in kidney transplantation over the past decade

被引:120
作者
Knoll, Greg [1 ,2 ]
机构
[1] Ottawa Hlth Res Inst, Ottawa, ON, Canada
[2] Univ Ottawa, Div Nephrol, Ottawa, ON, Canada
关键词
D O I
10.2165/00003495-200868001-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kidney transplantation offers patients with end-stage renal disease the greatest potential for increased longevity and enhanced quality of life; however, the demand for kidneys far exceeds the available supply, This has led to an increase in the number of people on waiting lists and an increase in waiting time. In the US, the overall median wait time was 2.85 years in 2004. The projected median waiting time for adult patients awaiting a deceased donor kidney in 2006 is 4.58 years. The renal transplant community has pursued multiple avenues in an attempt to increase the donor pool, but this remains a major challenge. In the last decade, the number of live donor kidney transplants performed in the US and Canada has doubled and represents just over 40% of all donor kidneys. Among deceased donor kidneys, the largest percentage increases were seen in expanded criteria donor and donation after cardiac death kidneys. In the last decade, the age distribution among donors, and among patients on waiting lists or receiving a renal transplant, has shifted towards older age groups. There have been dramatic shifts in baseline immunosuppression with increased usage of induction agents and the nearly universal replacement of azathioprine by mycophenolate. Additionally, tacrolimus use has increased from 13% to 79% at discharge, while ciclosporin (cyclosporine) use has fallen from 76% to 15%. Although 1-year graft survival rates are excellent, only modest improvements have been observed in long-term graft survival rates in the last decade. Thus, efforts have shifted from improving early graft outcomes to altering the natural Course of late graft failure. Death of transplant recipients from cardiovascular disease, infection and cancer remains an important limitation in kidney transplantation. Continued success in kidney transplantation will require increased numbers of donors, both living and deceased, as well as reduction in the primary causes of late transplant loss, namely premature patient death with a functioning graft and chronic allograft nephropathy.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 31 条
[1]   Long-term patient survival: Strategies to improve overall health [J].
Adams, PL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) :S65-S85
[2]   mTOR inhibition and its effect on cancer in transplantation [J].
Andrassy, J ;
Graeb, C ;
Rentsch, M ;
Jauch, KW ;
Guba, M .
TRANSPLANTATION, 2005, 80 (01) :S171-S174
[3]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[4]   Malignancy after transplantation [J].
Buell, JF ;
Gross, TG ;
Woodle, ES .
TRANSPLANTATION, 2005, 80 (02) :S254-S264
[5]   Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma [J].
Campistol, JM ;
Gutierrez-Dalmau, A ;
Torregrosa, JV .
TRANSPLANTATION, 2004, 77 (05) :760-762
[6]   Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation [J].
Campistol, Josep M. ;
Eris, Josette ;
Oberbauer, Rainer ;
Friend, Peter ;
Hutchison, Brian ;
Morales, Jose M. ;
Claesson, Kerstin ;
Stallone, Giovanni ;
Russ, Graeme ;
Rostaing, Lionel ;
Kreis, Henri ;
Burke, James T. ;
Brault, Yves ;
Scarola, Joseph A. ;
Neylan, John F. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (02) :581-589
[7]  
*CORR, 2005, EST REP TRANSPL WAIT
[8]   Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment [J].
Garcia, VD ;
Bonamigo, JL ;
Neumann, J ;
Fogliatto, L ;
Geiger, AM ;
Garcia, CD ;
Barros, V ;
Keitel, E ;
Bittar, AE ;
des Santos, AF ;
Roithmann, S .
TRANSPLANT INTERNATIONAL, 2003, 16 (03) :202-206
[9]   ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends [J].
Grassmann, A ;
Gioberge, S ;
Moeller, S ;
Brown, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (12) :2587-2593
[10]   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].
Guba, M ;
von Breitenbuch, P ;
Steinbauer, M ;
Koehl, G ;
Flegel, S ;
Hornung, M ;
Bruns, CJ ;
Zuelke, C ;
Farkas, S ;
Anthuber, M ;
Jauch, KW ;
Geissler, EK .
NATURE MEDICINE, 2002, 8 (02) :128-135